Skip to content

Study of Forceps Cannulation During ERCP

SOCCER: Study Of forCeps Cannulation During ERcp

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05336630
Acronym
SOCCER
Enrollment
152
Registered
2022-04-20
Start date
2022-05-12
Completion date
2024-10-21
Last updated
2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-ERCP Acute Pancreatitis

Brief summary

A difficult cannulation has been identified as one of the high risk factors for developing post-ERCP pancreatitis (PEP). The accessibility and morphology of the papilla influence the level of cannulation difficulty. The use of a forceps to assist in the cannulation is a demonstrated effective technique for cannulating papillae that are difficult to access. Thus, the objective of our study is to determine whether a forceps assisted cannulation leads to less difficult cannulation during ERCP. Because difficult cannulation is associated with increased risk of PEP, our study investigates whether the forceps assisted cannulation also reduces the incidence of PEP as a secondary outcome. Eligible patients who have consented will either be randomized to cannulation with forceps or cannulation with no forceps.

Detailed description

Endoscopic retrograde cholangiopancreatography (ERCP), an invasive procedure that combines endoscopy and x-ray to treat issues with the bile and pancreatic ducts, carries a two to ten percent risk of causing post-ERCP pancreatitis (PEP) \[1\]. Because acute pancreatitis is a devastating inflammatory condition that leads to extensive morbidity and mortality, efforts to reduce the risk of PEP in patients undergoing ERCP would enhance patient outcomes and would decrease the economic burden in treating PEP nationwide \[2-4\]. A difficult cannulation has been identified as one of the high risk factors for developing PEP \[5\]. A study performed by Scandinavian Association for Digestive Endoscopy (SADE) determined that cannulations with five or more attempts, a duration of five minutes or longer, or two or more unintended pancreatic duct (PD) wire passages significantly increased one's risk for PEP \[6\]. Thus, SADE defined a difficult cannulation as any cannulation with at least one of the following conditions: five or more attempts, five or more minutes, or two or more unintended PD wire passages \[6\]. This classification of a difficult cannulation has been adopted and standardized by the European Society of Gastrointestinal Endoscopy \[7\]. Because no current guidelines defining a difficult cannulation exist from the American College of Gastroenterology or American Gastroenterological Association, the European Society of Gastrointestinal Endoscopy (ESGE) guidelines as gathered from the SADE study are the worldwide standardized definition of difficult cannulation. Difficult cannulations have been reported to occur at a frequency of 42 percent for all ERCP exams \[8\]. The morphology and accessibility of the papilla influence the level of difficulty. Some studies have indicated that different macroscopic appearances of the papilla result in varying cannulation difficulty levels. Based on a study gauging intraobserver and interobserver agreement to the macroscopic appearance of different papillae, papillae are categorized as: Type 1, normal appearing; Type 2, small; Type 3, protruding or pendulous; and Type 4, ridged or creased \[9\]. Haraldsson et al. found that Type 2 and Type 3 papillae were more difficult to cannulate \[8\]. Regardless of papilla type, the involvement of a trainee (a GI fellow) resulted in more difficult cannulations \[8\]. In addition, the presence of redundant tissue, such as periampullary diverticula-which occurs in up to 20 percent of patients undergoing ERCP-results in more challenging cannulations \[10\]. The use of a forceps to assist in the cannulation is a demonstrated effective technique for cannulating papillae that are difficult to access \[10-12\]. The forceps clears the redundant tissue to enable access to the papilla, as well as stabilizes the ampullary position to permit an easier cannulation \[10\]. Currently, no randomized controlled trials that detail to what extent a forceps facilitates cannulation exist. Thus, our study aims to determine whether a forceps assisted cannulation reduces the incidence of difficult cannulations and consequently PEP. The primary outcome is difficult cannulation after randomization. A difficult cannulation will be defined as any cannulation that results in any of the following: 5 or more minutes, 5 or more cannulation attempts, or 2 or more unintentional pancreatic wire passages. The secondary outcome is PEP. Acute pancreatitis according to the Atlanta guidelines, is at least two of the following: abdominal pain consistent with pancreatitis, lipase or amylase greater than 3 times the upper limit of normal, radiographic evidence of pancreatitis on cross sectional imaging \[13\]. The study intervention is the use of a forceps during the cannulation. Eligible patients who have consented will either be randomized to forceps assisted cannulation or no forceps used during cannulation. The forceps is an FDA approved instrument and does not put the patient at any higher risk for any adverse event. SOCCER plans to enroll 152 patients. All patients undergoing ERCP at Dartmouth-Hitchcock endoscopy will be approached and consented for this study. Medical records will be reviewed to see if they meet inclusion/exclusion criteria. Patients will be consented day of the procedure. We received an approved HIPAA Authorization Waiver because access to a patient's chart will be required to determine inclusion/exclusion criteria. Consent will be performed in the endoscopy pre-op area. During the standard of care ERCP, the patients will be randomized intraoperatively to either cannulation with forceps and cannulation with no forceps. Written informed consent will be reviewed and signed before any study related procedures are performed. Please note that the primary outcome refers to a difficult cannulation AFTER randomization when the secondary inclusion criteria has been met. For example, if the secondary inclusion criteria met is difficult cannulation, then the primary outcome would be if from that point forward there were a difficult cannulation. As such, a total cannulation time of 10 minutes would enable the patient to be eligible (the first 5 minutes means the cannulation is difficult) and would mean the subject met the primary outcome (the second 5 minutes means cannulation after randomization is difficult). However, a total cannulation time of 8 minutes means the patient is eligible for the study (first 5 minutes means the cannulation is difficult) but did not meet the primary outcome (after randomization, the cannulation was not difficult because it was only 3 minutes). In a sense, the difficult cannulation clock is reset after randomization. If the secondary inclusion criteria met instead is papilla location or type, then the patient is randomized immediately before the cannulation and the difficult cannulation clock starts then. Measurement of difficult cannulation starts immediately after randomization upon the doctor's first cannulation attempt following randomization. Randomization will occur in block format. Randomization assignments will be placed in sealed manila envelopes that will be opened at the time of randomization. Manila envelopes will be kept with the study coordinator. After consent, data will be collected before, during, and after the procedure. The primary outcome will be measured during the procedure, whereas the secondary outcome will be determined during the 5 day follow up call. The study coordinator, GI fellow, or attending physician will call the patient 5 days (+/- 2 days) post-procedure to determine whether the patient developed PEP. Though it is preferred to contact the patient, other methods (chart review, emergency contact, outside records) are acceptable for determining the secondary outcome.

Interventions

DEVICEForceps

The forceps clears the redundant tissue to enable access to the papilla, as well as stabilizes the ampullary position to permit an easier cannulation. The forceps is an FDA approved instrument and does not put the patient at any higher risk for any adverse event. Please note that for the explicit purpose of the study the forceps will be used to grab tissue and not take biopsies. The forceps may still be used to take biopsies if the physician believes it is indicated.

Sponsors

Dartmouth-Hitchcock Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Masking description

Patients will be unblinded to their treatment on the 5 (+/- 2) day follow-up call.

Intervention model description

Patients will be randomized to either ERCP with forceps assisted cannulation or ERCP with no forceps.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

PRIMARY INCLUSION CRITERIA: * Patient consent * ERCP done on native papilla SECONDARY INCLUSION CRITERIA: * Papilla in a diverticulum * Papilla on rim of a diverticulum * Difficult cannulation (5 attempts, 5 minutes, or 2 unintended PD wire passages) * Redundant tissue overlying papilla * Type 2, 3, or 4 papilla

Exclusion criteria

* Prior ampullectomy * Known pregnancy, positive test, breastfeeding * Clinical contraindication to ERCP * Metal allergy * Prior sphincterotomy * Inability to follow protocol * \<18 years old * Enrolled in another ERCP study * Biliary/PD stent in place

Design outcomes

Primary

MeasureTime frameDescription
Cannulation Success Rate and Difficult Cannulation RateBaseline (during the ERCP)A difficult cannulation will be defined as any cannulation that results in any of the following: 5 or more minutes, 5 or more cannulation attempts, or 2 or more unintentional pancreatic wire passages.

Secondary

MeasureTime frame
Number of Post-ERCP Pancreatitis (PEP)5 (+/- 2) days after ERCP

Countries

United States

Participant flow

Participants by arm

ArmCount
Forceps-assisted Group
n=70 Age, years (SD) 61.9 (16.3) Gender Male, n (%) 33 (47.1) Female, n (%) 37 (52.9) BMI, kg/m2 29.3 ERCP indication Choledocholithiasis, n (%) 29 (41.4) Extrahepatic malignant biliary obstruction, n (%) 20 (28.6) Intrahepatic malignant biliary obstruction, n (%) 4 (5.7) Chronic pancreatitis 2 (2.9) Sphincter of oddi dysfunction, n (%) 0 (0) Pancreatic stone disease, n (%) 0 (0) Bile leak, n (%) 5 (7.1) Pancreatic fistula, n (%) 1 (1.4) Dorsal duct intervention, n (%) 1 (1.4) Other, n (%) 8 (11.4) Trainee involvement, n (%) 43 (61.4) Papilla classification type I, n (%) 45 (64.3) II, n (%) 6 (8.6) III, n (%) 14 (20.0) IV, n (%) 5 (7.1) Papilla located within a diverticulum, n (%) 4 (5.7) Reason for randomization Failed initial cannulation, n (%) 35 (50.0) Papilla classification type, n (%) 21 (30.0) Papilla location, n (%) 14 (20.0)
70
No Forceps-assisted Cannulation
n=81 Age, years (SD) 68.3 (13.3) Gender Male, n (%) 32 (39.5) Female, n (%) 49 (60.5) BMI, kg/m2 27.5 ERCP indication Choledocholithiasis, n (%) 37 (45.7) Extrahepatic malignant biliary obstruction, n (%) 19 (23.5) Intrahepatic malignant biliary obstruction, n (%) 4 (4.9) Chronic pancreatitis 2 (2.5) Sphincter of oddi dysfunction, n (%) 0 (0) Pancreatic stone disease, n (%) 0 (0) Bile leak, n (%) 4 (4.9) Pancreatic fistula, n (%) 1 (1.2) Dorsal duct intervention, n (%) 0 (0) Other, n (%) 14 (17.3) Trainee involvement, n (%) 51 (63.0) Papilla classification type I, n (%) 64 (79.0) II, n (%) 5 (6.2) III, n (%) 8 (9.9) IV, n (%) 4 (4.9) Papilla located within a diverticulum, n (%) 8 (9.9) Reason for randomization Failed initial cannulation, n (%) 45 (55.6) Papilla classification type, n (%) 11 (13.6) Papilla location, n (%) 25 (30.9)
81
Total151

Baseline characteristics

CharacteristicForceps-assisted GroupNo Forceps-assisted CannulationTotal
Age, Continuous61.9 years
STANDARD_DEVIATION 16.3
68.3 years
STANDARD_DEVIATION 13.3
65.0 years
STANDARD_DEVIATION 15
BMI29.3 kg/m^2
STANDARD_DEVIATION 7.4
27.5 kg/m^2
STANDARD_DEVIATION 7.1
28.4 kg/m^2
STANDARD_DEVIATION 7.2
ERCP indication
Bile leak
5 Participants4 Participants9 Participants
ERCP indication
Choledocholithiasis
29 Participants37 Participants66 Participants
ERCP indication
Chronic pancreatitis
2 Participants2 Participants4 Participants
ERCP indication
Dorsal duct intervention
1 Participants0 Participants1 Participants
ERCP indication
Extrahepatic malignant biliary obstruction
20 Participants19 Participants39 Participants
ERCP indication
Intrahepatic malignant biliary obstruction
4 Participants4 Participants8 Participants
ERCP indication
Other
8 Participants14 Participants22 Participants
ERCP indication
Pancreatic fistula
1 Participants1 Participants2 Participants
ERCP indication
Pancreatic stone disease
0 Participants0 Participants0 Participants
ERCP indication
Sphincter of oddi dysfunction
0 Participants0 Participants0 Participants
Fellow involvement in ERCP procedure43 Participants51 Participants94 Participants
Papilla located within a diverticulum4 Participants8 Participants12 Participants
Papilla morphologic classification type
I
45 Participants64 Participants109 Participants
Papilla morphologic classification type
II
6 Participants5 Participants11 Participants
Papilla morphologic classification type
III
14 Participants8 Participants22 Participants
Papilla morphologic classification type
IV
5 Participants4 Participants9 Participants
Race and Ethnicity Not Collected0 Participants
Reason for randomization
Failed initial cannulation
35 Participants45 Participants80 Participants
Reason for randomization
Papilla classification type
21 Participants11 Participants32 Participants
Reason for randomization
Papilla location
14 Participants25 Participants39 Participants
Region of Enrollment
United States
70 participants81 participants151 participants
Sex: Female, Male
Female
37 Participants32 Participants69 Participants
Sex: Female, Male
Male
33 Participants49 Participants82 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 700 / 81
other
Total, other adverse events
2 / 702 / 81
serious
Total, serious adverse events
5 / 709 / 81

Outcome results

Primary

Cannulation Success Rate and Difficult Cannulation Rate

A difficult cannulation will be defined as any cannulation that results in any of the following: 5 or more minutes, 5 or more cannulation attempts, or 2 or more unintentional pancreatic wire passages.

Time frame: Baseline (during the ERCP)

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Forceps-assisted GroupCannulation Success Rate and Difficult Cannulation RateSuccessful cannulation70 Participants
Forceps-assisted GroupCannulation Success Rate and Difficult Cannulation RateUnsuccessful cannulation0 Participants
No Forceps-assisted CannulationCannulation Success Rate and Difficult Cannulation RateSuccessful cannulation68 Participants
No Forceps-assisted CannulationCannulation Success Rate and Difficult Cannulation RateUnsuccessful cannulation13 Participants
Secondary

Number of Post-ERCP Pancreatitis (PEP)

Time frame: 5 (+/- 2) days after ERCP

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Forceps-assisted GroupNumber of Post-ERCP Pancreatitis (PEP)4 Participants
No Forceps-assisted CannulationNumber of Post-ERCP Pancreatitis (PEP)3 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026